Compare Quest Diagnostics Inc (DGX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NIO Inc. — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while NIO Inc. trades at $4.57 (market cap $11.59B). The key difference: Quest Diagnostics Inc is far larger — about 2.3× NIO Inc.'s market cap, and Quest Diagnostics Inc pays a 1.45% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| DGX | NIO | |
|---|---|---|
Market Cap | $26.21B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $7.89 |
52-Week Low | $173.49 | $4.44 |
Enterprise Value | $31.97B | $10.82B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
NIO's stock trades at $4.555, down 5.5% in the last session amid a bearish technical signal and negative cash flow trends. The company shows revenue growth with 2025 sales reaching $87.49 billion, but remains unprofitable with a net loss of $15.57 billion. Recent news highlights delivery growth and policy support for EVs in China, yet investor sentiment is mixed due to competitive pressures and high cash burn.
The outlook is cautious; while analyst consensus leans bullish with 54% buy ratings, fundamental weaknesses in profitability and negative equity pose significant risks. Upside depends on sustained revenue expansion and cost control, but volatility from market sentiment and execution challenges warrants careful monitoring for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
